PURPOSE OF REVIEW
Circulating tumor DNA (ctDNA) is increasingly used for molecular profiling in breast cancer, and its role as a longitudinal biomarker is expanding. This review examines recent evidence on serial ctDNA assessment, focusing on minimal residual disease (MRD) and molecular relapse in early breast cancer (...
G. R. Oliva, M. Cristofanilli, C. Reduzzi et al.· Current Opinion in Obstetric...· 0 citations
LB is progressively shifting from a research tool to a clinical decision-making instrument in HR+/HER2- mBC, and integrated multiparametric LB approaches combining CTCs and ctDNA are crucial to improve prognostic accuracy and clinical decision-making.
V. Frescura, M. Cristofanilli, C. Reduzzi et al.· Current Opinion in Oncology· 0 citations
A comprehensive overview of current knowledge on its applications in IBC is provided, highlighting the potential of circulating biomarkers to enhance disease characterization, diagnosis, risk assessment, and personalized treatment and the promising role of artificial intelligence in improving diagnostic accuracy.
E. Nicolò, M. Manai, Amr S. Soliman et al.· Critical reviews in oncology...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.